6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations

M. Bocchino, R. Cobuccio, M. De Martino, G. Rea, A. Matarese, A. Canora, C. Vitale, A. A. Stanziola, A. Sanduzzi (Naples, Italy)

Source: International Congress 2014 – ILDs 6
Session: ILDs 6
Session type: Thematic Poster Session
Number: 3798
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Abstract

Despite there is no definitive reference to the role of the 6-minute walk test (6MWT), it is frequently used to assess overall cardiopulmonary fitness and predict outcome in patients with diffuse interstitial lung diseases. Aim of the present study was to assess 6MWT performance with the Spiropalm devise (that allows a combined evaluation of lung function parameters and pulse-oxymetry) in a group of patients affected by clinically stable idiopathic pulmonary fibrosis (n=15) and fibrotic non specific interstitial pneumonia (n=8). Overall, there were 17 males with a mean age±SD: 65±9yrs. Twelve were ex-smokers. Significant O₂ desaturation was detectable in all cases (p<0.0001) with a mean distance walked of 404 m (78% of predicted) accounting for a 6MW work of 30685 kg*m. Ventilation and tidal volume were significantly increased at the end of 6MWT (15.3 vs 45.6 L/min and 0.6 vs 1.1 L, respectively), while the respiratory reserve was decreased (77 vs 35 %, p<0.0001). The distance-saturation product (DSP), that is the product of distance walked and lowest O₂ saturation, was 322±110 m%, while the desaturation-distance ratio (DDR), that is the ratio between the desaturation area (difference between maximal SpO₂ and patient's SpO₂ every 2 seconds) and distance walked, was 8.5±5.5. DDR was inversely correlated with both FVC and DLCO (r=-0.5, p=0.04, and r=-0.66, p=0.004). A positive correlation was instead found with the composite physiologic index (r=0.66, p=0.006). Spiropalm may be successfully applied to ameliorate 6MWT performance in fibrotic idiopathic interstitial pneumonias. Performance upon incremental oxygen supplementation should be investigated.


Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Bocchino, R. Cobuccio, M. De Martino, G. Rea, A. Matarese, A. Canora, C. Vitale, A. A. Stanziola, A. Sanduzzi (Naples, Italy). 6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations. Eur Respir J 2014; 44: Suppl. 58, 3798

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparison of physiological impairment in ILD patients with and without diagnostic IPF features
Source: International Congress 2014 – ILDs 4
Year: 2014


Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO
Source: International Congress 2014 – ILDs 6
Year: 2014


Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 3
Year: 2014


Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014


Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014


Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort
Source: International Congress 2014 – ILDs 4
Year: 2014


Recent improvement of survival of acute exacerbation in idiopathic interstitial pneumonias: 10 years experience
Source: International Congress 2014 – ILDs 2
Year: 2014

Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014


Evolution of an interstitial lung disease MDT: 5.5 years of data
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014


IPFdatabase – A new tool for a correct application of idiopathic pulmonary fibrosis guidelines
Source: International Congress 2014 – ILDs 2
Year: 2014

The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2014 – ILDs 1
Year: 2014


Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 2
Year: 2014

Assessment of nutritional status in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Year: 2016


Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment
Source: International Congress 2014 – ILDs 5
Year: 2014


Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014

Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014


Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS
Source: International Congress 2014 – ILDs 4
Year: 2014

Clinical data, lung function and cardiopulmonary exercise testing in CPFE (combined pulmonary fibrosis with emphysema). Results of a cohort of 20 patients
Source: International Congress 2014 – ILDs 6
Year: 2014

Six-minute walk test desaturation and echocardiographic findings in IPF: Correlational observations made in the European IPF registry (eurIPFreg)
Source: International Congress 2014 – ILDs 2
Year: 2014

Diffuse dendriform pulmonary ossification in a usual interstitial pneumonia-like distribution: A distinct entity or a variant of idiopathic pulmonary fibrosis?
Source: International Congress 2014 – ILDs 1
Year: 2014